Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cell therapy for Duchenne muscular dystrophy
IRCT20250805066763N1Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mesenchymal stem cells in Duchenne muscular dystrophy (DMD), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Effectiveness of transplantation, Age and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on IRCT20250805066763N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250805066763N1.